Published: 20 October 2022
Author(s): Jorge Álvarez-Troncoso, Lucía López-Caballero, Ángel Robles-Marhuend, Clara Soto-Abánades, Juan José Ríos-Blanco
Section: Letter to the Editor

Systemic autoimmune diseases (SAID) are a heterogeneous group of diseases with a common etiopathogenic basis, often requiring immunosuppressive therapies (DMARD) [1]. Although case-control studies reported no significant differences in coronavirus disease 2019 (COVID-19) outcomes, large population-based studies analyzing baseline risk factors reported a 2–3 times higher rate of poor outcomes in patients with SAID [1].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.